Learn About Cardiogenic Shock
Cardiogenic shock takes place when the heart is unable to supply enough blood and oxygen to the organs of the body.
Shock - cardiogenic
The most common causes of cardiogenic shock are serious heart conditions. Many of these occur during or after a heart attack (myocardial infarction). These complications include:
- A large section of heart muscle that no longer moves well or does not move at all
- Breaking open (rupture) of the heart muscle due to damage from the heart attack
- Dangerous heart rhythms, such as ventricular tachycardia, ventricular fibrillation, or supraventricular tachycardia
- Pressure on the heart due to a buildup of fluid around it (pericardial tamponade)
- Tear or rupture of the muscles or tendons that support the heart valves, especially the mitral valve
- Tear or rupture of the wall (septum) between the left and right ventricles (lower heart chambers)
- Very slow heart rhythm (bradycardia) or problem with the electrical system of the heart (heart block)
Cardiogenic shock occurs when the heart is unable to supply as much blood as the body needs. It can happen even if there hasn't been a heart attack. For example, if one of these problems listed above occurs and your heart function drops suddenly. Or if a valve becomes obstructed or if a combination of problems occurs.
Symptoms include:
- Chest pain or pressure
- Coma
- Decreased urination
- Fast breathing
- Fast pulse
- Heavy sweating, moist skin
- Lightheadedness
- Loss of alertness and ability to concentrate
- Restlessness, agitation, confusion
- Shortness of breath
- Skin that feels cool to the touch
- Pale skin color or blotchy skin
- Weak (thready) pulse
Cardiogenic shock is a medical emergency. You will need to stay in the hospital, most often in the Intensive or Coronary Care Unit (ICU). The goal of treatment is to find and treat the cause of shock to save your life.
You may need medicines to increase blood pressure and improve heart function, including:
- Dobutamine
- Dopamine
- Epinephrine
- Levosimendan
- Milrinone
- Norepinephrine
- Vasopressin
These medicines may help in the short-term. They are not often used for a long time.
When a heart rhythm disturbance (dysrhythmia) is serious, urgent treatment may be needed to restore a normal heart rhythm. This may include:
- Electrical "shock" therapy (defibrillation or cardioversion)
- Implanting a temporary pacemaker
- Medicines given through a vein (IV)
You may also receive:
- Pain medicine
- Oxygen
- Fluids, blood, and blood products through a vein (IV)
Other treatments for shock may include:
- Cardiac catheterization with coronary angioplasty and stenting
- Heart monitoring to guide treatment
- Heart surgery (coronary artery bypass surgery, heart valve replacement, left ventricular assist device)
- Intra-aortic balloon counterpulsation (IABP) to help the heart work better
- Pacemaker
- Ventricular assist device or other mechanical support
Trustees Of Columbia University In The City Of New York
Hiroo Takayama is a Thoracic Surgeon and a General Surgeon in New York, New York. Dr. Takayama is rated as an Elite provider by MediFind in the treatment of Cardiogenic Shock. His top areas of expertise are Cardiogenic Shock, Thoracic Aortic Aneurysm, Aortic Dissection, Heart Transplant, and Lung Transplant.
Rutgers Health-Rwj Scleroderma Program
Maya Guglin is a Cardiologist and a Transplant Surgeon in New Brunswick, New Jersey. Dr. Guglin is rated as an Elite provider by MediFind in the treatment of Cardiogenic Shock. Her top areas of expertise are Heart Failure, Cardiogenic Shock, Cardiomyopathy, Heart Transplant, and Lung Transplant. Dr. Guglin is currently accepting new patients.
University Of Texas Southwestern Medical Center At Dallas
Maryjane Farr is an Advanced Heart Failure and Transplant Cardiologist and a Cardiologist in Dallas, Texas. Dr. Farr is rated as an Elite provider by MediFind in the treatment of Cardiogenic Shock. Her top areas of expertise are Heart Failure, Cardiogenic Shock, Cardiomyopathy, Pulmonary Edema, and Heart Transplant.
In the past, the death rate from cardiogenic shock ranged from 80% to 90%. In more recent studies, this rate has decreased to 50% to 75%.
When cardiogenic shock is not treated, the outlook is very poor.
Complications may include:
- Brain damage
- Kidney damage
- Liver damage
Go to the emergency room or call 911 or the local emergency number if you have symptoms of cardiogenic shock. Cardiogenic shock is a medical emergency.
You may reduce the risk for developing cardiogenic shock by:
- Quickly treating its cause (such as heart attack or heart valve problem)
- Preventing and treating the risk factors for heart disease, such as diabetes, high blood pressure, high cholesterol and triglycerides, or tobacco use
Summary: The objective of this Phase 1b trial is to evaluate the safety and tolerability of procizumab, a monoclonal antibody under development for the treatment of cardiogenic shock (CS). CS is a life-threatening hypoperfusion of vital organs that frequently results in death. In addition to safety and tolerability, pharmacokinetics and pharmacodynamics of procizumab are evaluated to define the optimum pha...
Summary: Registry intended to provide a data repository and reporting infrastructure for the surveillance of CytoSorb device use in real-world critical care settings, and to serve as an objective, comprehensive, and scientifically-based resource to measure and improve the quality of patient care
Published Date: May 27, 2024
Published By: Michael A. Chen, MD, PhD, Associate Professor of Medicine, Division of Cardiology, Harborview Medical Center, University of Washington Medical School, Seattle, WA. Also reviewed by David C. Dugdale, MD, Medical Director, Brenda Conaway, Editorial Director, and the A.D.A.M. Editorial team.
Felker GM, Teerlink JR. Diagnosis and management of acute heart failure. In: Libby P, Bonow RO, Mann DL, Tomaselli GF, Bhatt DL, Solomon SD, eds. Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine. 12th ed. Philadelphia, PA: Elsevier; 2022:chap 49.
McMurray JJV, Pfeffer MA. Heart failure: treatment and prognosis. In: Goldman L, Cooney KA, eds. Goldman-Cecil Medicine. 27th ed. Philadelphia, PA: Elsevier; 2024: chap 46.
Rogers JG, O'Connor CM. Heart failure: epidemiology, pathobiology, and diagnosis. In: Goldman L, Cooney KA, eds. Goldman-Cecil Medicine. 27th ed. Philadelphia, PA: Elsevier; 2024: chap 45.